Head-to-head evidence
QLM3003 vs ZL-82
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: JAK · full Atopic Dermatitis pipeline
QLM3003
Developed by Qilu Pharmaceutical
NCT06058000 · Phase 2 · completed
The study was randomized, quadruple-blind, placebo-controlled, and enrolled 120 participants, with a clinical disease-activity endpoint (EASI-75). However, no primary endpoint results or statistical comparison are available, so the trial provides well-designed but currently incomplete evidence.
Next expected readout: March 2027 · NCT06880276 (registry estimate)
ZL-82
Developed by Chengdu Zenitar Biomedical Technology
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT07193589 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: QLM3003's landscape · ZL-82's landscape